Please login to the form below

Not currently logged in
Email:
Password:

New finance head for Xenon

Ian Mortimer joins from Tekmira

Xenon Pharmaceuticals has appointed Ian Mortimer as chief financial officer.

Mortimer will join Xenon on November 1, 2013. He has more than 15 years' experience in the biotechnology sector.

Currently with Tekmira Pharmaceuticals Corporation, as executive VP and chief financial officer, Mortimer is responsible for all aspects of the company's finance and capital markets activities and led Tekmira's listing on Nasdaq in 2010.

Prior to joining Tekmira, Mortimer was chief financial officer at Inex Pharmaceuticals Corporation. He has an MBA from Queen's University, a BSc in microbiology from the University of British Columbia and is a Certified Management Accountant.

"We are delighted to welcome Ian to the team. He brings a combination of strong financial and operations experience that is highly relevant to Xenon," said Dr Simon Pimstone, Xenon's president and CEO.

"Given our pipeline of approved, development stage and discovery stage products and programmes, together with our strong balance sheet and our suite of major pharmaceutical partnerships, this is a good time for Xenon to be adding an experienced CFO like Ian to the company," Pimstone added.

13th September 2013

From: Sales

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics